Introduction
Integrins are a large family of transmembrane heterodimeric receptors that, once bound to extracellular matrix proteins, regulate a variety of cellular processes. [1] As a consequence of their role in important physiological phenomena, integrin defects have been implicated in many common diseases.
Hence, it is not surprising that some integrins have become attractive targets for pharmacological intervention in a number of pathological conditions. [2] The observation that a V b 3 , a V b 5 and a 5 b 1 integrin subtypes are essential for tumor angiogenesis and can be successfully inhibited by small-molecule ligands has turned them into the focus of cancer research. [3] Across their extracellular a/b subunit interface containing the metal ion-dependent adhesion site (MIDAS), integrins recognize and bind protein ligands through contiguous tripeptide sequences, the majority of which are present within flexible loop regions and contain an acidic residue. [4] Several integrins, including a 5 b 1 and a V integrins, recognize ArgGly-Asp (RGD) sequences in endogenous ligands. The context of the ligand RGD sequence (flanking residues, three dimensional presentation) and individual features of the integrin binding pockets determine the recognition specificity and efficacy. A major breakthrough for understanding this interaction at a molecular level came in 2002 when the Xray structure of the complex of integrin a V b 3 with cyclo-[Arg-Gly-Asp-d-Phe-N(Me)-Val] (Cilengitide) was revealed. [5] This potent a V b 3 ligand was developed by Kessler and co-workers (Figure 1 ), [6, 7] and is currently in phase III clinical trials as an angiogenesis inhibitor for patients with glioblastoma multiforme. [8] The high activity and selectivity of this derivative has been attributed to an extended conforAbstract: The synthesis of eight bifunctional diketopiperazine (DKP) scaffolds is described; these were formally derived from 2,3-diaminopropionic acid and aspartic acid (DKP-1-DKP-7) or glutamic acid (DKP-8) and feature an amine and a carboxylic acid functional group. The scaffolds differ in the configuration at the two stereocenters and the substitution at the diketopiperazinic nitrogen atoms. The bifunctional diketopiperazines were introduced into eight cyclic peptidomimetics containing the Arg-Gly-Asp (RGD) sequence. The resulting RGD peptidomimetics were screened for their ability to inhibit biotinylated vitronectin binding to the purified integrins a v b 3 and a v b 5 , which are involved in tumor angiogenesis. Nanomolar IC 50 values were obtained for the RGD peptidomimetics derived from trans DKP scaffolds (DKP-2-DKP-8).
Conformational studies of the cyclic RGD peptidomimetics by 1 mation of the RGD motif displaying a distance of about 9 between the C b atoms of Asp and Arg. [5] These observations prompted many other research groups to investigate the use of conformationally constrained cyclic RGD peptides and peptidomimetics as active and selective integrin ligands, encompassing a wide variety of rigid scaffolds and featuring 13-, 14-, 15-and 16-membered rings ( Figure 1 ). [9] Among the successful approaches, we would like to mention the g-amino acid RGD peptidomimetics containing a g-aminocyclopentane carboxylic acid or a 4-aminoproline residue (14-membered ring), [10] the azabicyclic lactam RGD peptidomimetics (15-membered ring, with the scaffold mimicking a constrained dipeptide, e.g., ST1646), [11] and the b-amino acid RGD peptidomimetics, embodying b 3 -homoamino acids [12] (13-membered ring) or a cis-b-aminocyclopropane carboxylic acid (16-membered ring). [13] Up to now, a large number of linear or cyclic peptidic and peptidomimetic ligands have been developed, which are all related to the common recognition motif RGD [14] and a few potent ligands are presently in different stages of clinical trials for cancer therapy. Notwithstanding these recent achievements, the discovery of new ligands displaying high activity and selectivity together with an optimal pharmacological profile still remains a challenge. Moreover, a clear-cut explanation of the geometrical requirements of the RGD peptidomimetics in their interaction with the different integrins is still lacking (the above-mentioned X-ray structural information suffers from a rather coarse resolution). [5] New bifunctional diketopiperazine (DKP) scaffolds [DKP-1 (cis) and DKP-2 (trans); Figure 2 ] were recently developed, which are formally derived from aspartic acid and 2,3-diaminopropionic acid and bear a carboxylic acid and an amino functionality. [15] These bifunctional diketopiperazines were introduced into the 17-membered cyclic RGD peptidomimetics cyclo-[DKP-1-RGD] (9) and cyclo-[DKP-2-RGD] (10; Figure 3 ), and their conformations and biological activities were investigated. [16] Cyclo-[DKP-2-RGD] (10) effectively inhibited biotinylated vitronectin binding to the purified a v b 3 receptor at low nanomolar concentration, whereas cyclo-[DKP-1-RGD] (9) required a micromolar concentration. [16] These results were interpreted in terms of a more extended RGD sequence imparted by the trans geometry of the diketopiperazine scaffold (DKP-2) to give rise to a better pre-organization of peptidomimetic 10 for binding to the integrin receptors. These observations prompted us to investigate the structural elements of the bifunctional diketopiperazine scaffold that are able to influence and possibly improve the binding of the cyclo-[DKP-RGD] peptidomimetics.
Herein we present a full account of our investigations and report: 1) the synthesis of a number of cyclic RGD peptidomimetics containing various diketopiperazine scaffolds with different stereochemistry and substitution at the piperazinic nitrogen atoms; 2) the ability of the cyclic RGD peptidomimetics to compete with biotinylated vitronectin for binding to the purified a v b 3 and a v b 5 receptors; 3) conformational studies of the cyclic RGD peptidomimetics in aqueous solution by 1 H NMR spectroscopy experiments; 4) conformational studies of the cyclic RGD peptidomimetics by Monte Carlo/Stochastic Dynamics (MC/SD) simulations; 5) docking studies of the cyclic RGD peptidomimetics in the crystal structure of the a v b 3 binding site.
Results and Discussion
Synthesis of the diketopiperazine scaffolds and cyclic RGD peptidomimetics: A collection of eight diketopiperazines www.chemeurj.org (DKP-1-DKP-8) was synthesized, and their stereochemistry and substitution patterns were varied ( Figure 2 ). In particular the scaffolds differ in: 1) the relative stereochemistry, namely cis (DKP-1) or trans (DKP-2-DKP-8); 2) the absolute stereochemistry of the trans scaffolds [3R,6S (DKP-2, DKP-4, DKP-5) or 3S,6R (DKP-3, DKP-6, DKP-7, DKP-8)]; 3) the substitution at the endocyclic nitrogen atoms, which can be either hydrogen or benzyl (DKP-2, DKP-3, DKP-4, DKP-6, DKP-8) or dibenzyl (DKP-5, DKP-7); 4) the length of the side-arm bearing the carboxylic group, which can be either carboxymethyl (DKP-1-DKP-7) or carboxyethyl (DKP-8).
Two different strategies were devised for the synthesis of DKP-1-DKP-8, depending on their nitrogen substitution. In particular, DKP-1, DKP-2 and DKP-3 (bearing a benzyl group at nitrogen N-4, Figure 2 ) were prepared by making use of the serine ligation strategy exemplified in Scheme 1, [17] starting from either (R)-or (S)-N-(tert-butoxycarbonyl)aspartic acid b-allyl ester 11 [18] or (R)-or (S)-Nbenzylserine methyl ester 12.
[19] Direct coupling of these fragments (HATU, iPr 2 NEt or EDC, DMAP) led to the isopeptides 14 in high yield, rather than forming the expected dipeptides 13. As a matter of fact, selective O-acylation of the unprotected b-hydroxyl group of N-benzylserine methyl ester is preferred to the formation of the tertiary amide and the resulting ester bond is stable in solution to O,N-acyl transfer. [17] The O,N-acyl migration was then triggered by cleavage of the Boc protecting group and treatment with a base, which also promoted the simultaneous cyclization to the diketopiperazine 15. The introduction of the nitrogen functionality was then realized through a Mitsunobu-type reaction by using HN 3 ·Tol in a toluene/dichloromethane solution, to obtain azide 16 in a moderate (51 %; cis: S,S) to good yield (80 %; trans: S,R or R,S). [20] Finally, a one-pot Staudinger reduction/Boc protection [21] yielded the DKP scaffold allyl ester 17, which was de-allylated [22] to give the amino acid derivatives DKP-1, DKP-2 and DKP-3 in a quantitative yield.
Scaffold DKP-8, bearing a carboxyethyl side chain, was obtained through a similar synthesis strategy starting from (S)-N-benzylserine methyl ester 12 and (R)-N-(tert-butoxycarbonyl)glutamic acid g-methyl ester 18 (Scheme 2). [23] Also in this case, direct coupling of the fragments afforded the isopeptide 19, which was deprotected and cyclized to the diketopiperazine 20. Azidation of the À CH 2 OH group through a Mitsunobu reaction, reduction by catalytic hydrogenation, protection with Boc 2 O and final hydrolysis of the methylester afforded DKP-8.
For the preparation of diketopiperazines DKP-4 and DKP-6 (bearing a benzyl group at nitrogen N-1, Figure 2 ), the coupling of Boc-serine to N-benzyl-aspartic acid diA C H T U N G T R E N N U N G meth-A C H T U N G T R E N N U N G ylester 21 [24] was envisaged (Scheme 3). The serine hydroxyl group required protection to avoid self-condensation, and the commercially available Boc-serine tert-butyl ether was initially treated with N-Bn-Asp dimethyl ester 21 by using several coupling agents: with HATU, [25] PyBrOP [26] and DPPA [27] no product was detected; use of the acyl fluoride, [obtained by treatment of Boc-SerA C H T U N G T R E N N U N G (OtBu) with cyanuric fluoride] afforded the coupling product in a modest 15 % yield, whereas use of the mixed anhydride [obtained by treatment of Boc-SerA C H T U N G T R E N N U N G (OtBu) with iBuOCOCl] gave the corresponding iso-butyl carbamate. Finally, preformation of the symmetric Boc-SerA C H T U N G T R E N N U N G (OtBu) anhydride (DCC) [28] and coupling to N-Bn-Asp dimethyl ester 21 afforded the corresponding dipeptide 22 in a satisfactory 80 % yield (Scheme 3).
In order to simplify the synthesis sequence and avoid the use of an additional protecting group (tBu), the hydroxyl group of Boc-Ser-OMe (either l or d) [20a] was directly transformed into the corresponding azide under Mitsunobu conditions in 78 % yield (Scheme 4).
The resulting product was then saponified with LiOH and the freshly prepared acid 23 was treated with DCC to give the symmetric anhydride 24 in a quantitative yield, which was isolated by filtering off DCU and solvent evaporation, and was immediately used in the next synthesis step without further purification. Coupling of 3-azido-2-N-tert-butoxycarbonylaminopropionic anhydride (24) to N-benzyl-aspartic acid dimethylester (21) occurred in 80 % yield, whereas the subsequent Boc cleavage and cyclization to diketopiperazine 26 were nearly quantitative (Scheme 5).
At this stage, diketopiperazine 26 was split in two portions. One portion was subjected to catalytic hydrogenation of the azide, Boc protection and final hydrolysis of the methyl ester to afford diketopiperazines DKP-4 and DKP-6 in 90 % overall yield (Scheme 6).
A second portion of diketopiperazine 26 was alkylated at nitrogen N-4 (benzyl bromide, KHMDS) to afford the corresponding bis-benzylated derivative. One-pot Staudinger reduction/Boc protection [21] followed by saponification of the methyl ester afforded DKP-5 and DKP-7 in 75 % overall yield (Scheme 7).
Diketopiperazines DKP-1-DKP-8 were then incorporated into the cyclic RGD derivatives 9, 10 and 27-32 ( Figure 4) . A solution phase synthesis strategy was adopted, by using Boc-ArgA C H T U N G T R E N N U N G (Mtr), Gly-OBn and Cbz-AspA C H T U N G T R E N N U N G (OtBu)-OH. The dipeptide Boc-ArgA C H T U N G T R E N N U N G (Mtr)-Gly-OBn was Boc-deprotected and coupled to the acid of the appropriate diketopiperazine scaffold. Subsequent Boc deprotection of the DKP amino group and coupling of the aspartic derivative Cbz-AspA C H T U N G T R E N N U N G (OtBu)-OH afforded the linear peptidomimetic Cbz-AspA C H T U N G T R E N N U N G (OtBu)-DKPArgA C H T U N G T R E N N U N G (Mtr)-Gly-OBn, which was deprotected by hydrogenolysis (Cbz and Bn) and was subjected to macrolactamization (for detailed conditions, see the Supporting Information). Several methodologies were screened for the ring closure, and the best yields were obtained for all the products (except 27) by using HATU/HOAT as coupling agents in a 1:4:4:6 substrate/HATU/ HOAT/iPr 2 NEt molar ratio and a substrate concentration of 1.4 mm in DMF.
[11b] In the case of cyclo-[DKP-3-RGD] (27) the highest yield (75 %) was obtained by using a 1:3:6 substrate/DPPA/iPr 2 NEt molar ratio with the same substrate concentration (1.4 mm) in DMF. [29] A final side-chain deprotection (TFA/thioanisole/ethanedithiol/anisole 90:5:3:2) and preparative HPLC purification afforded the desired compounds 9, 10 and 27-32 for the biological screening.
In the case of the N-dibenzyl derivatives 29 and 31, the molecules can exist as two different separable conformers (diastereomers) due to hindered rotation of one ring around the other, in a way reminiscent of the ansa-cyclopeptides [30] (i.e., the DKP N-benzyl group cannot pass inside the macrolactam ring).
With 29, we were able to isolate only one diastereomer, either because it was formed exclusively or because it was formed predominantly and the minor one was not detected/ isolated. With 31, two diastereomers were isolated in a 2(A):1(B) ratio ( Figure 5 ). The two diastereomers were formed in the macrolactamization step, as shown by the two sets of peaks (2:1 ratio) in the 1 H NMR spectrum (see the Supporting Information), but co-eluted in the HPLC. However, after side-chain deprotection, the two diastereomers could be separated, analyzed and subjected to the binding assays (vide infra).
Integrin receptor competitive binding assays: The cyclic RGD peptidomimetics were examined in vitro for their ability to inhibit biotinylated vitronectin binding to the purified a v b 3 and a v b 5 receptors (Table 1) .
Screening assays were performed by incubating the immobilized integrin receptors with various concentrations (10 À12 -10 À5 m) of the RGD ligands 9, 10, 27-32 in the presence of biotinylated vitronectin (1 mg mL À1 ), and measuring the concentration of bound vitronectin in the presence of the competitive ligands. The ability of the new compounds to inhibit the binding of vitronectin to the isolated a v b 3 and a v b 5 receptors was compared with that of the reference compounds cA C H T U N G T R E N N U N G (RGDfV) [31] and ST1646 [11] ( Figure 1 ). The results are collected in Table 1 . Low nanomolar values were obtained with all the ligands except cyclo-[DKP-1-RGD] (9), which incorporates a cis DKP, and ligand 31 A. The behavior of this last ligand is peculiar, considering that the diastereomeric compound 31 B (see above for the definition of the two diastereomers) is the most potent ligand of this series, and it effectively inhibits the binding of vitronectin to the isolated a v b 3 receptor in subnanomolar concentration. Interestingly, unlike reference compounds cA C H T U N G T R E N N U N G (RGDfV) and ST1646, the RGD peptidomimetics 10 and 27-32 were about 10-500-fold more selective for the a v b 3 integrin with respect to the a v b 5 in this kind of assay.
NMR spectroscopy characterization and conformational studies: The structure and connectivity of ligands 9, 10 and 27-32 and of their fully protected precursors were unambiguously assigned by means of mono-and bidimensional 1 Hand 13 C NMR spectroscopy. The preferred conformations of the cyclic RGD peptidomimetics 9, 10 and 27-32 in aqueous solution were then investigated, with the aim of rationalizing the affinity of these compounds for the a v b 3 receptor at a molecular level.
H NMR spectroscopy experiments were conducted to detect intramolecular hydrogen bonds, by measuring the chemical shift of the N À H protons and their temperature coefficients (Dd/DT). NOESY spectra were recorded to investigate both sequential and long-range NOEs that provide evidence for preferred conformations. The relevant NMR spectroscopy data are summarized in Table 2 .
As already mentioned in our preliminary studies, [16] low affinity ligand 9 exists as an equilibrium of two different preferred conformations. The NOESY spectrum shows two mutually exclusive long-range NOE contacts. The crosspeak between DKP-NH 10 High affinity ligands 10 and 27 are apparently characterized by conformational mobility, as suggested by the values of chemical shifts and Dd/DT reported in Table 2 . The only exception is proton NH-Asp of 27 (d = 7.85 ppm, Dd/DT = À3.5 ppb K À1 ), which might be involved in a type II H-bonding pattern (for definition of type II H-bonding pattern see Figure 6 B). On the other hand, the presence in both cases of a NOE contact between NH Gly and NH Arg suggests the formation of a b-turn motif at DKP-Arg, stabilized by a hydrogen bond between NH Gly and C(5)=O (referred to as type III H-bonding pattern, Figure 7 ). The presence of this H bond is also supported by the rather upfield chemical shift value of NH Gly in these two ligands (d = 8.18 and 8.00 ppm for 10 and 27, respectively) and the relatively low temperature dependence (À5.7 and À4.5 ppb K
À1
, respectively). The similarity of the NMR spectroscopy data and, hence, of the conformation of these two ligands is quite surprising, considering the opposite configuration of the diketo- www.chemeurj.org piperazine scaffold [DKP-2 (3R,6S) in 10; DKP-3 (3S,6R) in 27], which should impart a different stereochemical orientation to the two side arms of the diketopiperazine. This conformational similarity can be interpreted in terms of a quasienantiomeric structure of the two ligands (excluding the configuration of the remote RD amino acid side chains, Figure 7 ). High affinity ligands 28 and 30, featuring the diketopiperazine scaffolds DKP-4 (3R,6S) and DKP-6 (3S,6R), respectively (with the benzyl substitution at the endocyclic nitrogen N-1, instead of N-4), show a different NMR pattern.
In particular, ligand 30 is characterized by a rather strong NOE contact between NH Asp and NH 10 and a moderate one involving NH 4 and NH 10 . These two contacts are mutually exclusive and are hence indicative of an equilibrium between two different conformations, respectively, type I and type IV binding modes (Figure 8 A and B) . The hydrogen bonded status of the two amide protons NH 4 ) and a quite upfield chemical shift value (d = 7.59 ppm) for proton NH 10 . These two features suggest a type I H-bonding pattern (for definition of type I H-bonding pattern, Figure 6 A or 8 A), notwithstanding the apparent lack of NOE contact between NH Asp and NH 10 .
The dibenzylated diketopiperazine containing peptidomimetics 29 and 31 were eventually studied. Ligand 29 shows NMR spectroscopy features similar to ligand 10 (for definition of type III H-bonding pattern, see Figure 7 ): a NOE contact between NH Gly and NH Arg and a rather shielded NH Gly (d = 8.23 ppm) with a relatively low temperature coefficient (À4.7 ppb K À1 ). As discussed in the synthesis section, ligand cyclo-[DKP-7-RGD] was obtained as a mixture of two diastereomers 31 A and 31 B, the conformations of which in solution were studied separately. In particular, the low affinity ligand 31 A displayed two mutually exclusive NOE contacts between NH Arg and NH Gly and between NH Asp and NH Gly . These three protons, on the other hand, show also a rather strong hydrogen bonded status, as indicated by their low temperature dependence and, at least for NH Asp and NH Gly , their upfield chemical shift (Table 2) . These data indicate an equilibrium between two different conformations: one displaying a type III H-bonding pattern (b-turn at DKP-Arg, Figure 7 ) and a second one showing a type II H-bonding pattern (b-turn at Arg-Gly, Figure 6 B), like the low-affinity ligand 9, that is, cyclo-[DKP-1-RGD]. Finally, high affinity ligand 31 B shows a single NOE contact between NH Asp and NH 10 and a hydrogen bonded status for NH 10 (d = 7.72 ppm and Dd/DT = À4 ppb K À1 , Table 2 ). These values are indicative of a type I H-bonding pattern (Figure 6 A or 8 A) .
Compound 32, containing the carboxyethyl diketopiperazine scaffold DKP-8, is characterized by temperature coefficients of amide protons (Table 2 ) greater than 5 ppb K À1 ; this suggests an equilibrium between different conformations. The NOESY spectrum of this ligand shows a strong long-range NOE contact that involves DKP-NH 1 and NH Arg (Figure 9 ). This contact is indicative of a conformation stabilized by a hydrogen bond between NH 1 and ArgÀC=O (referred to as type V H-bonding pattern). The involvement of NH 1 in a hydrogen bond is also confirmed by its relatively low chemical shift value (d = 7.75 ppm).
Computational studies
Conformational analysis: Conformational studies of the cyclic RGD peptidomimetics were performed by mixedmode Metropolis Monte Carlo/Stochastic Dynamics (MC/ SD) simulations, [32] by using the implicit water GB/SA solvation model [33] and the OPLS_2001 force field. [34, 35] As outlined in the Introduction, a key parameter for the RGD fit- ting into the active site of the a V b 3 integrin is the distance of about 9 between the C b atoms of Asp and Arg, imparted by an extended conformation of the Arg-Gly-Asp sequence. [5] In such an extended conformation, the carboxylate and guanidinium groups are properly positioned to effectively exert their function of electrostatic clamp (vide infra for the relevant docking studies).
As mentioned in our preliminary studies, [16] three-dimensional structures satisfying long-range NOE contacts were generated for low affinity ligand 9 by performing two 10 ns restrained MC/SD simulations and applying the DKP-NH 10 / NH Asp or the NH Asp /NH Gly distance restraint derived from the NOESY spectra described in the relevant section above. More than 90 % of the conformations sampled during the first simulation adopted a non-extended arrangement of the RGD sequence characterized by a b-turn at Gly-Asp and the presence of the corresponding hydrogen bond between DKP-NH 10 and Arg-C=O. In addition, the formation of a gturn at Gly stabilized by the hydrogen bond between NH Asp and Arg-C=O was observed for 40 % of the simulation. A CbA C H T U N G T R E N N U N G (Arg)ÀCbA C H T U N G T R E N N U N G (Asp) average distance of 7.4 was obtained during this MC/SD calculation. A representative energy minimized conformation selected by cluster analysis and featuring both H bonds is shown in Figure 10 A (type I-cis H-bonding pattern).
Approximately 60 % of the conformations sampled during the simulation of 9 featuring the NH Asp /NH Gly distance restraint, adopted a non-extended arrangement of the RGD sequence characterized by a b-turn at Arg-Gly and the corresponding hydrogen bond between NH Asp and C(8)=O. In addition, the formation of a g-turn at Arg stabilized by the hydrogen bond between NH Gly and C(8)=O was observed for 40 % of the simulation. The CbA C H T U N G T R E N N U N G (Arg) À CbA C H T U N G T R E N N U N G (Asp) average distance in this MC/SD calculation was 6.8 . A representative energy minimized conformation selected by cluster analysis and featuring both H bonds is shown in Figure 10 ) and an upfield chemical shift value (d = 7.59 ppm) for proton NH 10 .
A representative energy minimized conformation selected by cluster analysis and featuring the H bond between DKP-NH 10 and Arg-C=O (type I-trans H-bonding pattern) is shown in Figure 11 B for RGD peptidomimetic 28. It is worth noting how the combination of the trans DKP-4 scaffold with the Gly-Asp b-turn occurs by generating an extended RGD arrangement, whereas the combination of the cis DKP-1 scaffold with the same secondary motif resulted in a non-extended RGD disposition (Figure 10 A) . Accordingly, two type I H-bonding patterns have been defined (type I-cis and type I-trans), depending on the cis or trans relative stereochemistry of the diketopiperazine scaffold.
Three-dimensional structures satisfying long-range NOE contacts were generated for high affinity ligand 30 (containing N-1-benzylated DKP-6, 3S,6R) by performing two 10 ns restrained MC/SD simulations and applying the DKP-NH 10 / NH Asp or the NH 4 /NH 10 distance restraint derived from NOESY spectra (Table 2, Figure 8) .
Most of the conformations sampled during the first simulation adopted an extended arrangement of the RGD se- and Gly-C=O. In addition, the formation of a g-turn at Asp stabilized by the hydrogen bond between NH 10 and Gly-C=O was observed for 50 % of the simulation. A representative energy minimized conformation selected by cluster analysis and featuring these H bonds is shown in Figure 12 B (type IV H-bonding pattern).
Three-dimensional structures satisfying long-range NOE contacts were generated for RGD peptidomimetic 31 (containing N-dibenzylated DKP-7, 3S,6R) by performing three 10 ns restrained MC/SD simulations and applying the following distance restraints derived from NOESY spectra of diastereoisomers 31 A and 31 B (Table 2) : in the first simulation a NH Arg /NH Gly restraint, relevant in 31 A, in the second simulation a NH Asp /NH Gly restraint, also relevant in 31 A, and in the third simulation a DKP-NH 10 /NH Asp restraint, relevant in 31 B.
All the conformations sampled during the first two simulations adopted a non-extended arrangement of the RGD sequence [CbA C H T U N G T R E N N U N G (Arg)ÀCbA C H T U N G T R E N N U N G (Asp) average distance of 6.6 ] characterized by the simultaneous presence of different turn motifs (pseudo-b-turn at DKP-Arg, g-turn at Gly and pseudo-b-turn centered at the DKP unit). The structural models provided by these restrained MC/SD simulations differ from the conformations hypothesized on the basis of NMR spectroscopy data of 31 A [equilibrium between type III (pseudo-b-turn at DKP-Arg) and type II (b-turn at ArgGly) H-bonding patterns, see the NMR spectroscopy section]. However, also the calculated structures are able to provide an explanation for the NOE contacts and the NMR temperature coefficients observed for low affinity ligand 31 A.
The distance restraint corresponding to the NOE contact between DKP-NH 10 Contrary to what was observed for the other cyclic RGD peptidomimetics containing DKP scaffolds, rotation of the DKP ring cannot be observed during the simulations performed on compound 31; this confirms 31 A and 31 B as two different separable conformers (diastereomers) due to hindered rotation of one ring around the other.
The distance restraint corresponding to the NOE contact between NH 1 and NH Arg was applied in the 10 ns MC/SD simulation of RGD peptidomimetic 32 (containing N-4-benzylated DKP-8, 3S,6R). Approximately 60 % of the conformations sampled during this simulation adopted an extended arrangement of the RGD sequence characterized by the formation of the hydrogen bond between NH 1 and Arg-C=O ( Figure 9 , type V H-bonding pattern). In addition, the formation of the hydrogen bond between NH Asp and C(2)=O (type Va H-bonding pattern) or the presence of a bturn at Gly-Asp stabilized by the hydrogen bond between DKP-NH 10 and Arg-C=O (type Vb H-bonding pattern) were observed for 35 and 25 % of the simulation, respectively.
Representative energy minimized conformations selected by cluster analysis and featuring the type Va and Vb Hbonding patterns are shown in Figure 13 for RGD peptidomimetic 32.
Molecular docking:
In order to rationalize, on a molecular basis, the affinity of cyclic RGD peptidomimetics for the a v b 3 receptor, docking studies were performed by starting from the representative conformations obtained from the MC/SD simulations. The crystal structure of the extracellular segment of integrin a v b 3 complexed with the cyclic pentapeptide Cilengitide (PDB ID: 1L5G) was taken as a reference model for the interpretation of the docking results in terms of ligand-protein interactions. [5] In the X-ray complex, Cilengitide binds to the interface of the a and b units forming specific electrostatic interactions. The acid and basic pharmacophoric groups and their orientation are essential for binding to the a v b 3 because they act like an electrostatic clamp, interacting with charged regions of the receptor binding site.
Docking calculations starting from geometries featuring the type I-cis and type II H-bonding patterns produced topranked binding modes conserving optimal interactions only with the a subunit of the a v b 3 receptor. Probably, the short CbA C H T U N G T R E N N U N G (Arg)ÀCbA C H T U N G T R E N N U N G (Asp) distances (values lower than 8 ) of these geometries prevent the guanidine and carboxylic groups from achieving the required separation for binding to the a v b 3 integrin. On the other hand, docking calculations starting from the RGD extended conformations featuring the type I-trans, type III, type IV and type V H-bonding pat-
top-ranked binding modes conserving all the important interactions of the X-ray complex. As an example, the best pose obtained for the highest affinity ligand 31 B featuring the type I-trans H-bonding pattern is shown in Figure 14 .
The positively charged Arg guanidinium group of the ligand interacts with the negatively charged side chains of Asp218 and Asp150 in the a unit, one carboxylate oxygen of the ligand Asp side chain is coordinated to the metal cation in the metal-ion-dependent adhesion site (MIDAS) region of the b unit, whereas the second carboxylate oxygen forms hydrogen bonds with the backbone amides of Asn215 and Tyr122 in the b unit. Further stabilizing interaction involves the formation of a hydrogen bond between the ligand backbone NH of the Asp residue and the backbone carbonyl group of Arg216 in the b unit. Favorable aromatic ring interactions between the ligand benzylic groups and the b 3 -Tyr122 side chain could also be observed (Figure 14) .
In light of all these considerations, the micromolar affinity of RGD peptidomimetics 9 and 31 A (3.9 and 0.2 mm, respectively) for a v b 3 (Table 1) can be explained in terms of their www.chemeurj.org low pre-organization for binding. In fact, as determined by the computational and NMR spectroscopy studies, in solution these compounds mainly feature non-extended RGD conformations, which according to the docking results, are not able to properly fit into the a v b 3 receptor. On the contrary, the nanomolar affinity of RGD peptidomimetics 10, 27-30, 31 B and 32 for a v b 3 can be attributed to their high structural pre-organization. In fact, as determined by the computational and NMR spectroscopy studies, these compounds in solution mainly feature extended RGD conformations (principally determined by type I-trans, type III, type IV and type V H-bonding patterns) similar to the RGD bound conformation of Cilengitide.
Conclusion
In summary, we have synthesized a small library of bifunctional diketopiperazine (DKP) scaffolds, which were formally derived from 2,3-diaminopropionic acid and aspartic acid (DKP-1-DKP-7) or glutamic acid (DKP-8) and feature an amine and a carboxylic acid functional group. The scaffolds differ for the configuration at the two stereocenters and the substitution at the diketopiperazinic nitrogen atoms. The bifunctional diketopiperazines were introduced into eight cyclic peptidomimetics containing the Arg-Gly-Asp (RGD) sequence. The resulting RGD peptidomimetics were screened for their ability to inhibit biotinylated vitronectin binding to the purified integrins 
Experimental Section
A detailed procedure for the synthesis of intermediate 15 starting from protected amino acid derivatives 11 and 12 was already reported. [16] The same procedure was used for the synthesis of intermediate 20, starting from protected amino acid derivatives 18 and 12. Diketopiperazine 26 ring closure was achieved under similar conditions by using Et 3 SiH (2.5 equiv) as a scavenger during Boc cleavage.
General procedure for the synthesis of diketopiperazine azides: PPh 3 (1.5 equiv) was added to a solution of diketopiperazines 15 or 20
(1 equiv) in CH 2 Cl 2 /toluene (2:1) under a nitrogen atmosphere and at À20 8C, and the mixture was stirred until a solution was obtained. Hydrazoic acid (1.5 m in toluene, 3 equiv) was added followed by dropwise addition of DIAD (1.5 equiv) and the reaction was stirred at À20 8C for 3-16 h. The reaction mixture was loaded onto a silica gel column and purified by flash chromatography (for solvents and ratios used, see the Supporting Information) to afford the desired product as a white foam (69-86 %).
General procedure for the synthesis of dipeptide 25: DCC (1 equiv) was added to a solution of either (R)-or (S)-N-Boc-Ser(N 3 )-OH (23; 2 equiv) in CH 2 Cl 2 , in one portion. A white precipitate (DCU) formed and stirring was continued for 1 h at room temperature. The mixture was then filtered on cotton wool to remove DCU. The white DCU residue was washed twice with cold CH 2 Cl 2 . The filtrate was concentrated under reduced pressure at room temperature, and dried under high vacuum to afford symmetric anhydride 24 as a pale yellow foam, which was used without further purification. Either (R)-or (S)-N-benzyl-aspartic acid dimethyl-A C H T U N G T R E N N U N G ester (0.7 equiv) was dissolved in CH 2 Cl 2 and the mixture was cooled to 0 8C. A solution of symmetric anhydride in CH 2 Cl 2 was then added dropwise (very slowly). The reaction mixture was allowed to reach room temperature and was stirred at room temperature, overnight. The solvent was then removed under reduced pressure and the residue was purified by flash chromatography (hexane/EtOAc 8:2) on silica gel to afford the desired product as a viscous transparent oil (80 %).
General diketopiperazine N-benzylation procedure: A flame-dried flask under N 2 was charged with a solution of 26 (1 equiv) in dry THF. The temperature was lowered to À78 8C and KHMDS (0.5 m solution in toluene, 1.1 equiv) was added dropwise. After 30 min benzyl bromide (5 equiv) was added, and a final solvent ratio THF/DMF 7:3 was reached by adding DMF. The mixture was allowed to reach À40 8C and stirred for 3 h. Then aqueous NH 4 Cl was slowly added and the mixture was extracted with EtOAc (3 ). The organic phases were then washed with brine and dried over Na 2 SO 4 . Volatiles were removed under reduced pressure and the residue was purified by flash chromatography on silica gel to afford the desired product as a viscous transparent oil (86 %).
General procedure for diketopiperazine azide reduction and Boc protection: A) 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 2.2 equiv) and Me 3 P (1m solution in toluene, 2 equiv) were added successively to a solution of diketopiperazine azide (1 equiv) in THF, under a nitrogen atmosphere and at À20 8C. After being stirred for 6 h at room temperature, the solution was diluted with CH 2 Cl 2 and washed with H 2 O (3 ) and brine. The organic phase was dried over Na 2 SO 4 and volatiles were removed under reduced pressure. The residue was purified by flash chromatography (for solvents and ratios used, see the Supporting Information) on silica gel to afford the desired product as a white foam (76-87 %). B) Diketopiperazine azide (1 equiv) was dissolved in THF and Pd/C (0.1 equiv) was added. The flask was thoroughly purged with H 2 , and the system was closed. The reaction mixture was stirred at room temperature for 4 h, and then filtered through a Celite pad. The cake thus obtained was thoroughly washed with THF. The filtrate was concentrated and dried to give the crude product as a transparent paste (95 %), which was dissolved in THF (35 mL). Boc 2 O (1.1 equiv) was then added in one portion. After stirring the mixture at room temperature, overnight, EtOAc was added. The solution was washed with KHSO 4 (1 m; 4 ) and brine (1 ). The organic phase was dried over Na 2 SO 4 and volatiles were removed under reduced pressure, to afford the desired product as a white foam (95 %), which was used without further purification.
General procedure for diketopiperazine allyl ester deprotection: Diketopiperazine allyl ester (1 equiv) was dissolved in CH 2 Cl 2 under a nitrogen atmosphere. After cooling the solution at 0 8C, pyrrolidine (1.2 equiv), PPh 3 (0.18 equiv) and [PdA C H T U N G T R E N N U N G (PPh 3 ) 4 ] (0.04 equiv) were added successively. After being stirred for 1 h at 0 8C, the mixture was diluted with EtOAc and extracted with aqueous NaHCO 3 (4 ) . The combined aqueous phases were acidified to pH 2 with a KHSO 4 (1 m) solution and then extracted with CH 2 Cl 2 . The resulting organic phase was dried over Na 2 SO 4 and the solvent was evaporated to afford the desired product as a fluffy white solid (99 %).
Procedure for diketopiperazine methyl ester hydrolysis: A) Diketopiperazine methyl ester (1 equiv) was dissolved in THF and the mixture was cooled to 0 8C. A solution of LiOH·H 2 O (2.5 equiv) in H 2 O was added dropwise. The resulting solution was stirred for 1 h at 0 8C. Then, maintaining the temperature at 0 8C, the mixture was acidified with HCl (1 m) to pH 1-2, and extracted with CH 2 Cl 2 (4 ). The collected organic phases were dried over Na 2 SO 4 and volatiles were removed under reduced pressure. Either DKP-4 or DKP-6 were afforded as a white foam (100 %). B) Diketopiperazine methyl ester (1 equiv) was dissolved in THF. The mixture was cooled to 0 8C and a solution of LiOH (2.7 m) in H 2 O 2 (35 % v/v) was added dropwise. The mixture was stirred for an additional 30 min at 0 8C, then warmed to room temperature and stirred for 7 h. After addition of Na 2 SO 3 (6 equiv) the reaction mixture was diluted with THF/H 2 O (1:1). KHSO 4 (1 m) was then added until pH 1-2 was reached, and the mixture was extracted with DCM (4 ). The collected organic phases were dried over Na 2 SO 4 and volatiles removed under reduced pressure, to afford crude DKP-8 as a yellowish solid. The crude product was dissolved in EtOAc and extracted with a saturated NaHCO 3 aqueous solution; collected aqueous layers were acidified with KHSO 4 (1 m) to reach pH 1-2, and extracted with DCM (4 ). Collected organic phases were dried over Na 2 SO 4 and volatiles were removed under reduced pressure, to afford DKP-8 as a white foam (90 %).
General procedure for Boc deprotection reactions: A half volume of TFA was added to a solution of the N-Boc-protected amino acid or peptide in CH 2 Cl 2 (0.13 m). The reaction mixture was stirred for 2 h at room temperature and then concentrated at reduced pressure. Excess TFA was azeotropically removed from the residue with toluene. Diethyl ether was added to the residue and the resulting suspension was evaporated under reduced pressure to afford the corresponding TFA salt.
General procedure for coupling reactions: HATU (1.2 equiv), HOAt (1.2 equiv) and DIPEA (4 equiv) were added successively to a solution of the N-protected amino acid in DMF, under a nitrogen atmosphere and at 0 8C. After 30 min, a solution of the N-deprotected TFA salt of the peptide in DMF was added and the reaction mixture was stirred at 0 8C for 1 h and at room temperature, overnight. The mixture was then diluted with EtOAc and consecutively washed with KHSO 4 (1 m; 2 ), a saturated NaHCO 3 aqueous solution (2 ), brine (2 ), and dried over Na 2 SO 4 . Volatiles were evaporated under reduced pressure to afford the crude product.
General procedure for Cbz and OBn hydrogenolytic cleavage: Protected compound (1 equiv) was dissolved in a mixture of THF/H 2 O (1:1) and Pd/C 10 % (0.1 equiv) was added. The reaction mixtures were subjected to three vacuum/hydrogen cycles and then stirred, overnight, at room temperature under 1 bar of hydrogen. The mixture was filtered through Celite, and the cake thus obtained was washed thoroughly with THF/ H 2 O (1:1). The filtrate was concentrated and dried to give the crude product as white solid (100 %).
General procedure for macrolactamization: HATU (4 equiv), HOAt (4 equiv) and DIPEA (6 equiv) were added successively to a solution of deprotected linear compound (1.4 mm; 1 equiv) in DMF, under a nitrogen atmosphere at 0 8C. After stirring the reaction mixture at 0 8C for 1 h, it was allowed to reach room temperature and stirred, overnight. DMF was then removed under reduced pressure and the residue was purified by flash chromatography (CH 2 Cl 2 /MeOH; for ratios used, see the Supporting Information) on silica gel to afford the product as white foam (31-74 %). ). An aliquot of diluted receptors (100 mL per well) was added to 96-well microtiter plates (Nunc MW 96F Medisorp Straight) and incubated, overnight, at 4 8C. The plates were then incubated with blocking solution (coating buffer plus 1 % bovine serum albumin) for an additional 2 h at room temperature to block nonspecific binding followed by 3 h incubation at room temperature with various concentrations (10
À12

-10
À5 m) of test compounds in the presence of vitronectine (1 mg mL À1 ) biotinylated by using EZ-Link Sulfo-NHS-Biotinylation kit (Pierce, Rockford, IL). After washing, the plates were incubated for 1 h at room temperature with streptavidin-biotinylated peroxidase complex (Amersham Biosciences, Uppsala, Sweden) followed by 30 min incubation with substrate reagent solution (100 mL; R&D Systems, Minneapolis, MN) before stopping the reaction by addition of H 2 SO 4 (2 N, 50 mL). Absorbance at 415 nm was read in a Synergy HT multi-detection microplate reader (BioTek Instruments, Inc.). Each data point is the result of the average of triplicate wells and was analyzed by nonlinear regression analysis with Prism GraphPad program. Each experiment was repeated in triplicate.
General procedure for Mtr and OtBu ester removal: Protected macrolactams were treated with TFA (0.01 m) in the presence of ion scavengers: thioanisole (5 %), ethanedithiol (3 %), anisole (2 %). After TFA removal, under reduced pressure, the residue was dissolved in a 1:1 mixture of di-A C H T U N G T R E N N U N G isopropyl ether/water. Phases were separated and the aqueous layer was washed several times with diisopropyl ether. The aqueous phase was concentrated under reduced pressure to give the crude product, which was purified by HPLC to give the desired compound as white solid (60-80 %).
NMR spectroscopy studies: NMR spectroscopy experiments were performed at a temperature of 298 K on Bruker Avance 400 and 600 MHz spectrometers. All proton and carbon chemical shifts were assigned unambiguously. The NMR experiments were carried out in a D 2 O/H 2 O 1:9 mixture in order to observe amide protons. Two-dimensional experiments (TOCSY, NOESY, and HSQC) were carried out on samples of cyclic RGD peptidomimetics 9, 10, 27-32 at a concentration range of 3-6 mm. NOESY experiments were performed at 0.7 or 0.8 s. The water resonance was saturated with the excitation sculpting sequence from the Bruker library. The conformations of the cyclic pentapeptides were analyzed with respect to hydrogen bonding of amide protons (VT-NMR spectroscopy) and NOE contacts.
Computational studies: All calculations were run by using the Schrçding-er suite of programs (http://www.schrodinger.com) through the Maestro graphical interface.
Conformational analysis: Conformational preferences of the RGD peptidomimetics were investigated by Monte Carlo/Stochastic Dynamics (MC/ SD) hybrid simulations [32] by using the NMR spectroscopy restraints derived from the experimental NOE contacts (for distance restraints used for each calculation, see the Supporting Information). All the NOE restraints were set to a distance value of 2A C H T U N G T R E N N U N G (AE0.5) with a force constant of 100 kJ mol À1 À2 . MC/SD simulations were performed at 300 K within the framework of MacroModel version 9.5 [36] by employing the OPLS_2001 force field [34] and the implicit water GB/SA solvation model. [33] RGD side-chain dihedral angles were defined as internal coordinate degrees of freedom in the Monte Carlo part of the algorithm. A time step of 1 fs was used for the stochastic dynamics (SD) part of the algorithm for 10 ns of simulation time. Samples were taken at 2 ps intervals during each simulation, yielding 5000 conformations for analysis. The percentages of H bonds discussed here were calculated as percentages of conformations sampled during the simulation in which donor H-acceptor O distance < 2.5 (g-turn) or < 4 (b-turn).
Molecular docking:
The recently solved crystal structure of the extracellular domain of the integrin a v b 3 receptor in complex with Cilengitide and in the presence of the proadhesive ion Mn 2 + (PDB ID: 1L5G) [5] was used for docking studies. Docking was performed only on the globular head of the integrin because the headgroup of integrin has been identified in the X-ray structure as the ligand-binding region. The protein structure was setup for docking as follows. The protein was truncated to residue sequences 41-342 for chain a and 114-347 for chain b. Due to a lack of parameters, the Mn 2 + ions in the experimental protein structure were modeled by replacing them with Ca 2 + ions. The resulting structure was prepared by using the Protein Preparation Wizard of the graphical user interface Maestro and the OPLSAA force field. The automated docking calculations were performed by using Glide [37] (Grid-based Ligand Docking with Energetics). The grid generation step started from the extracellular fragment of X-ray structure of a v b 3 complex with Cilengitide, as described in the protein setup section. The center of the grid enclosing box was defined by the center of the bound ligand, as described www.chemeurj.org in the original PDB entry. The enclosing box dimensions, which are automatically deduced from the ligand size, fit the entire active site. For the docking step, the size of the bounding box for placing the ligand center was set to 12 . No further modifications were applied to the default settings. The GlideScore function was used to select 20 poses for each ligand. The Glide program was initially tested for its ability to reproduce the crystallized binding geometry of Cilengitide. The program was successful in reproducing the experimentally determined binding mode of this compound, as it corresponds to the best-scored pose.
